SIGNIFICANCE OF BASELINE ACE ACTIVITY IN PATIENTS WITH METABOLIC SYNDROME WHEN ADMINISTRATION OF ACE INHIBITORS AND IMIDAZOLINE AGONISTS IS CONSIDERED

Abstract

Significance of baseline ACE activity in patients with metabolic syndrome when administration of ACE inhibitors and imidazoline agonists is considered.